Enzo Biochem, Inc. is a bioscience company focusing on delivering and applying technology capabilities to produce products and services. The Company's segments include Enzo Clinical Labs, Enzo Life Sciences and Enzo Therapeutics. Enzo Clinical Labs is a clinical reference laboratory providing a range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies. It offers a menu of molecular and other clinical laboratory tests or procedures. Enzo Life Sciences manufactures, develops and markets products and tools to clinical research, drug development and bioscience research customers. Enzo Therapeutics is a biopharmaceutical venture that develops multiple approaches in the areas of gastrointestinal, infectious, ophthalmic and metabolic diseases. Its products in the development pipeline include a range of assays for detection of various women's health infectious agents, as well as for use in the identification of pathogens for other markets.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Medical & Diagnostic Laboratories
- Sub-Industry: N/A
- Symbol: NYSE:ENZ
- CUSIP: N/A
- Web: www.enzo.com
Capitalization:- Market Cap: $484.95 million
- Outstanding Shares: 46,407,000
Average Prices:- 50 Day Moving Avg: $11.08
- 200 Day Moving Avg: $9.80
- 52 Week Range: $4.88 - $12.04
P/E:- Trailing P/E Ratio: 14.66
- Foreward P/E Ratio: -348.33
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $106.24 million
- Price / Sales: 4.56
- Book Value: $1.91 per share
- Price / Book: 5.47
Profitability:- EBIDTA: ($202,000.00)
- Net Margins: 31.57%
- Return on Equity: -5.13%
- Return on Assets: -4.17%
Debt:- Current Ratio: 5.16%
- Quick Ratio: 4.74%
Misc:- Average Volume: 198,980 shs.
- Beta: 0.92
- Short Ratio: 2.45
Frequently Asked Questions for Enzo Biochem (NYSE:ENZ)
What is Enzo Biochem's stock symbol?
Enzo Biochem trades on the New York Stock Exchange (NYSE) under the ticker symbol "ENZ."
How were Enzo Biochem's earnings last quarter?
Enzo Biochem, Inc. (NYSE:ENZ) released its quarterly earnings data on Wednesday, June, 8th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.06) by $0.02. The company had revenue of $18.16 million for the quarter, compared to analyst estimates of $24.50 million. Enzo Biochem had a negative return on equity of 5.13% and a net margin of 31.57%. During the same period in the previous year, the company posted ($0.07) EPS. View Enzo Biochem's Earnings History.
Who are some of Enzo Biochem's key competitors?
Some companies that are related to Enzo Biochem include Quality Systems (QSII), Athenex (ATNX), Editas Medicine (EDIT), Cardiovascular Systems (CSII), Pharmerica Corporation (PMC), K2M Group Holdings (KTWO), Intellia Therapeutics (NTLA), Amarin Corporation PLC (AMRN), Retrophin (RTRX), BeyondSpring (BYSI), Luminex Corporation (LMNX), ZIOPHARM Oncology (ZIOP), NeoGenomics (NEO), Eagle Pharmaceuticals (EGRX), REGENXBIO (RGNX), Orthofix International N.V. (OFIX), Intersect ENT (XENT) and Intra-Cellular Therapies (ITCI).
Who are Enzo Biochem's key executives?
Enzo Biochem's management team includes the folowing people:
- Barry W. Weiner, President, Chief Financial Officer, Principal Accounting Officer, Treasurer, Director
- Elazar Rabbani Ph.D., Chairman of the Board, Chief Executive Officer, Secretary
- James M. O'Brien, Executive Vice President - Finance
- David C. Goldberg, Vice President - Corporate Development, General Manager of Enzo Clinical Labs
- Dieter Schapfel M.D., Chief Medical Director
- Bruce A. Hanna Ph.D., Director
- Gregory M. Bortz, Independent Director
- Dov Perlysky, Independent Director
Who owns Enzo Biochem stock?
Enzo Biochem's stock is owned by many different of institutional and retail investors. Top institutional investors include Evermore Global Advisors LLC (7.66%), Renaissance Technologies LLC (4.46%), Dimensional Fund Advisors LP (4.37%), Vanguard Group Inc. (3.78%), Acadian Asset Management LLC (2.38%) and Gilder Gagnon Howe & Co. LLC (2.15%). View Institutional Ownership Trends for Enzo Biochem.
Who sold Enzo Biochem stock? Who is selling Enzo Biochem stock?
Enzo Biochem's stock was sold by a variety of institutional investors in the last quarter, including First Light Asset Management LLC, GSA Capital Partners LLP, Wells Fargo & Company MN, Acadian Asset Management LLC, Nationwide Fund Advisors, Kopp Investment Advisors LLC, Eagle Global Advisors LLC and Arrowstreet Capital Limited Partnership. View Insider Buying and Selling for Enzo Biochem.
Who bought Enzo Biochem stock? Who is buying Enzo Biochem stock?
Enzo Biochem's stock was bought by a variety of institutional investors in the last quarter, including Evermore Global Advisors LLC, Dimensional Fund Advisors LP, Gilder Gagnon Howe & Co. LLC, TIAA CREF Investment Management LLC, Mckinley Capital Management LLC Delaware, Alliancebernstein L.P., Marathon Capital Management and Abner Herrman & Brock LLC. View Insider Buying and Selling for Enzo Biochem.
How do I buy Enzo Biochem stock?
Shares of Enzo Biochem can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Enzo Biochem's stock price today?
One share of Enzo Biochem stock can currently be purchased for approximately $10.45.
MarketBeat Community Rating for Enzo Biochem (NYSE ENZ)MarketBeat's community ratings are surveys of what our community members think about Enzo Biochem and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Enzo Biochem (NYSE:ENZ) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | No ratings tracked in the last 12 months. |
| Consensus Rating: | N/A (Score: NaN) |
| Consensus Price Target: | N/A |
Analysts' Ratings History for Enzo Biochem (NYSE:ENZ)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 2/9/2016 | Dawson James | Reiterated Rating | Buy | | N/A |  |
(Data available from 9/24/2015 forward)
Earnings History for Enzo Biochem (NYSE:ENZ)Earnings History by Quarter for Enzo Biochem (NYSE ENZ)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 3/13/2017 | Q2 2017 | ($0.04) | ($0.02) | $26.10 million | $26.26 million | View | N/A | |
| 12/8/2016 | Q117 | ($0.05) | ($0.03) | $25.90 million | $26.28 million | View | N/A | |
| 10/13/2016 | Q416 | ($0.06) | ($0.04) | $26.00 million | $26.60 million | View | N/A | |
| 6/8/2016 | Q316 | ($0.06) | ($0.04) | $24.50 million | $18.16 million | View | N/A | |
| 3/9/2016 | Q216 | ($0.06) | ($0.07) | $24.43 million | $24.60 million | View | N/A | |
| 12/7/2015 | Q116 | ($0.05) | ($0.05) | $25.00 million | $25.18 million | View | N/A | |
| 10/13/2015 | Q415 | ($0.06) | ($0.06) | $24.60 million | $25.70 million | View | Listen | |
| 6/9/2015 | Q315 | ($0.06) | ($0.07) | $24.40 million | $23.99 million | View | N/A | |
| 3/12/2015 | Q215 | ($0.09) | ($0.09) | $24.20 million | $23.09 million | View | N/A | |
| 12/9/2014 | Q114 | ($0.08) | ($0.08) | $24.50 million | $24.82 million | View | Listen | |
| 10/9/2014 | Q4 2014 | ($0.07) | ($0.06) | $23.60 million | $24.91 million | View | Listen | |
| 6/9/2014 | Q314 | ($0.09) | ($0.05) | $22.80 million | $24.00 million | View | N/A | |
| 3/11/2014 | Q2 | ($0.08) | ($0.09) | $22.00 million | $22.93 million | View | Listen | |
| 12/11/2013 | Q1 | ($0.06) | ($0.07) | | | View | Listen | |
| 10/16/2013 | Q413 | | ($0.08) | $22.00 million | $23.30 million | View | Listen | |
| 6/10/2013 | Q3 2013 | | ($0.15) | $22.20 million | $22.60 million | View | Listen | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Enzo Biochem (NYSE:ENZ)Current Year EPS Consensus Estimate: $-0.07 EPS
Next Year EPS Consensus Estimate: $-0.03 EPS
Dividend History for Enzo Biochem (NYSE:ENZ)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Enzo Biochem (NYSE:ENZ)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Enzo Biochem (NYSE:ENZ)
Latest Headlines for Enzo Biochem (NYSE:ENZ)
| Source: |
|
| Date | Headline |
|---|
 | Enzo Biochem Schedules Teleconference to Discuss Fourth Quarter 2017 Results Thursday September 28, 2017 at 8 ... - Business Wire (press release)
www.businesswire.com - September 23 at 3:27 AM |
 | Enzo Biochem Schedules Teleconference to Discuss Fourth Quarter 2017 Results Thursday September 28, 2017 at 8:30 AM E.T.
finance.yahoo.com - September 22 at 5:23 PM |
 | Enzo Biochem Is Now Oversold (ENZ)
www.thestreet.com - September 19 at 6:20 PM |
| Enzo Biochem, Inc. breached its 50 day moving average in a Bullish Manner : ENZ-US : September 1, 2017
finance.yahoo.com - September 1 at 6:40 PM |
| Enzo Biochem, Inc. – Value Analysis (NYSE:ENZ) : August 25, 2017
finance.yahoo.com - August 25 at 7:59 PM |
| Enzo Biochem, Inc. breached its 50 day moving average in a Bearish Manner : ENZ-US : August 17, 2017
finance.yahoo.com - August 17 at 7:31 PM |
 | BRIEF-Enzo Biochem says federal judge in a U.S. Court has entered an order in action entitled Enzo Life Sciences v. Abbott Laboratories
www.reuters.com - August 16 at 9:03 PM |
 | Enzo Biochem, Inc. (ENZ) Downgraded by Zacks Investment Research
www.americanbankingnews.com - August 15 at 6:08 PM |
| Geron's (GERN) Imetelstat Progressing Well, Setbacks Concern
finance.yahoo.com - August 14 at 6:42 PM |
 | The Medicines Company (MDCO) Q2 Loss Widens, Revenues Miss
www.nasdaq.com - August 11 at 12:38 AM |
| Perrigo (PRGO) Q2 Earnings & Sales Top, 2017 View Raised
finance.yahoo.com - August 10 at 7:35 PM |
| Catalyst (CPRX) Posts Narrower than Expected Loss in Q2
finance.yahoo.com - August 10 at 7:35 PM |
| Orexigen (OREX) Q2 Loss Narrows, Contrave Sales Impress
finance.yahoo.com - August 9 at 6:28 PM |
| Jazz Pharma (JAZZ) Q2 Earnings & Revenues Miss, View Intact
finance.yahoo.com - August 9 at 6:28 PM |
| Epizyme (EPZM) Incurs Narrower-than-Expected Loss in Q2
finance.yahoo.com - August 7 at 6:34 PM |
| Juno Therapeutics (JUNO) Q2 Loss Widens, Revenues Surpass
finance.yahoo.com - August 4 at 6:33 PM |
| Strongbridge Biopharma (SBBP) Rises: Stock Moves 17% Higher
finance.yahoo.com - August 1 at 6:57 PM |
| Dr. Reddy's (RDY) Earnings Decline Y/Y in Q1, Sales Rise
finance.yahoo.com - July 31 at 6:03 PM |
| Enzo Biochem, Inc. (ENZ) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - July 29 at 5:59 PM |
 | Immunoprotein Diagnostic Testing Market Worth $10.3 Billion by 2025: Grand View Research, Inc.
www.marketwatch.com - July 27 at 11:54 PM |
| Bristol-Myers (BMY) Beats on Q2 Earnings, Tweaks 2017 View - Nasdaq
www.nasdaq.com - July 27 at 6:51 PM |
| Bristol-Myers (BMY) Beats on Q2 Earnings, Tweaks 2017 View
finance.yahoo.com - July 27 at 6:51 PM |
| GlaxoSmithKline (GSK) Beats on Q2 Earnings, Lowers Guidance
finance.yahoo.com - July 27 at 6:51 PM |
| Galapagos (GLPG) Looks Good: Stock Adds 6.2% in Session
finance.yahoo.com - July 21 at 8:14 PM |
| Valeant (VRX) To Sell Obagi for $190 Million to Lower Debt
finance.yahoo.com - July 19 at 4:43 PM |
| Perrigo Company Gets FDA Approval for Generic Topical Gel
finance.yahoo.com - July 18 at 7:51 PM |
| Can Enzo Biochem (ENZ) Run Higher on Strong Earnings Estimate ... - Nasdaq
www.nasdaq.com - July 14 at 4:10 PM |
| Can Enzo Biochem (ENZ) Run Higher on Strong Earnings Estimate Revisions?
finance.yahoo.com - July 14 at 4:10 PM |
| Gilead (GILD) Application for HIV Drug Validated in EU
finance.yahoo.com - July 14 at 4:10 PM |
| 5 Stocks with Recent Price Strength to Enhance Your Returns
finance.yahoo.com - July 13 at 7:40 PM |
| BioDelivery-Purdue Pharma Ink Marketing Deal for Pain Drug
finance.yahoo.com - July 13 at 7:40 PM |
| Mallinckrodt to Pay $35M for Controlled Substances Probe - Nasdaq
www.nasdaq.com - July 13 at 12:07 AM |
| Roche (RHHBY) Announces Positive Data on Hemophilia A Drug
finance.yahoo.com - July 11 at 7:28 PM |
 | Enzo Biochem Rounds The Corner
seekingalpha.com - July 10 at 6:12 PM |
| ETFs with exposure to Enzo Biochem, Inc. : July 10, 2017
finance.yahoo.com - July 10 at 6:12 PM |
| Head to Head Review: Enzo Biochem (NYSE:ENZ) vs. NeoGenomics (NEO)
www.americanbankingnews.com - July 1 at 4:04 PM |
| Enzo Biochem (ENZ) and RadNet (RDNT) Financial Comparison
www.americanbankingnews.com - July 1 at 12:14 AM |
| Enzo Biochem Reports Delaware Court Ruling
finance.yahoo.com - June 29 at 7:51 PM |
| Surging Earnings Estimates Signal Good News for Enzo Biochem (ENZ)
finance.yahoo.com - June 22 at 10:01 AM |
| Looking for a Top Momentum Stock? 3 Reasons Why Enzo Biochem (ENZ) is a Great Choice
finance.yahoo.com - June 21 at 6:33 PM |
| Enzo Biochem, Inc. (ENZ) Raised to "Buy" at Zacks Investment Research
www.americanbankingnews.com - June 20 at 10:30 PM |
| ETFs with exposure to Enzo Biochem, Inc. : June 19, 2017
finance.yahoo.com - June 19 at 7:37 PM |
| Zacks: Enzo Biochem, Inc. (ENZ) Given $8.00 Average Target Price by Analysts
www.americanbankingnews.com - June 15 at 4:20 PM |
 | Top 5 Biotech Stocks as of June 2017 (JAZZ, ENZ)
www.investopedia.com - June 14 at 11:07 PM |
| Enzo Biochem, Inc. :ENZ-US: Earnings Analysis: Q3, 2017 By the Numbers : June 12, 2017
finance.yahoo.com - June 12 at 5:53 PM |
| Enzo Biochem, Inc.: Strong price momentum but will it sustain?
finance.yahoo.com - June 12 at 5:53 PM |
| Edited Transcript of ENZ earnings conference call or presentation 9-Jun-17 12:30pm GMT
finance.yahoo.com - June 9 at 10:29 PM |
| Mid-Afternoon Market Update: NASDAQ Down 2.5%; DuPont Fabros Shares Spike Higher
www.nasdaq.com - June 9 at 5:27 PM |
| Enzo Biochem's (ENZ) Q3 2017 Results - Earnings Call Transcript
seekingalpha.com - June 9 at 5:27 PM |
| ETFs with exposure to Enzo Biochem, Inc. : June 9, 2017
finance.yahoo.com - June 9 at 5:27 PM |
Enzo Biochem (ENZ) Chart for Sunday, September, 24, 2017
